International Journal of Otolaryngology

Research Article

Sex-Related Differences in Outcomes for Oropharyngeal Squamous Cell Carcinoma by HPV Status

Table 3

Adjusted Cox proportional hazard models for overall survival (OS) and head and neck cancer-specific survival (HNCSS) by sex^∗.


	OS				HNCSS
	Men median, mo	Women median, mo	HR (95% CI)	value	Men median, mo	Women median, mo	HR (95% CI)	value

HPV positive
All stages	—	—	1.05 (0.90–1.22)	0.57	—	—	1.21 (0.98–1.49)	0.08
Rec Trt	—	—	1.06 (0.89–1.28)	0.51	—	—	1.18 (0.91–1.51)	0.21
Stage I	—	—	0.94 (0.73–1.21)	0.61	—	—	1.12 (0.78–1.60)	0.53
Rec Trt	—	—	0.94 (0.70–1.27)	0.70	—	—	1.09 (0.72–1.65)	0.69
Stage II	—	—	1.13 (0.83–1.56)	0.43	—	—	1.46 (0.97–2.20)	0.07
Rec Trt	—	—	0.99 (0.68–1.44)	0.97	—	—	1.17 (0.71–1.92)	0.55
Stage III	80	—	1.21 (0.90–1.62)	0.20	—	—	1.36 (0.93–2.01)	0.11
Rec Trt	—	—	1.35 (0.96–1.88)	0.08	—	—	1.50 (0.97–2.31)	0.07
Stage IV	20	23	0.95 (0.57–1.59)	0.86	—	35	0.91 (0.44–1.89)	0.81
Rec Trt	32	31	1.01 (0.48–2.11)	0.98	—	—	0.61 (0.18–2.06)	0.42

HPV negative
All stages	61	42	1.15 (1.02–1.29)	0.02^∗	—	—	1.17 (0.99–1.38)	0.06
Rec Trt	81	50	1.28 (1.11–1.47)	0.001^∗	—	—	1.30 (1.07–1.59)	0.009^∗
Stage I	76	62	1.45 (0.90–2.32)	0.13	—	—	1.11 (0.49–2.50)	0.80
Rec Trt	—	62	1.57 (0.95–2.60)	0.08	—	—	1.18 (0.49–2.82)	0.72
Stage II	74	62	1.15 (0.76–1.72)	0.51	—	—	1.31 (0.72–2.39)	0.37
Rec Trt	74	62	1.27 (0.83–1.94)	0.27	—	—	1.48 (0.80–2.74)	0.21
Stage III	—	51	1.13 (0.83–1.53)	0.45	—	—	0.97 (0.64–1.47)	0.88
Rec Trt	—	62	1.43 (1.01–2.01)	0.04^∗	—	—	1.09 (0.67–1.80)	0.72
Stage IVA	69	38	1.20 (1.01–1.43)	0.04^∗	—	—	1.27 (1.00–1.61)	0.05^∗
Rec Trt	81	47	1.22 (0.99–1.50)	0.06	—	—	1.38 (1.05–1.83)	0.02^∗
Stage IVB	28	11	1.33 (0.93–1.91)	0.12	—	36	2.02 (1.26–3.24)	0.003^∗
Rec Trt	48	18	1.72 (1.05–2.82)	0.03^∗	—	41	2.64 (1.40–4.98)	0.003^∗
Stage IVC	10	10	0.95 (0.63–1.43)	0.80	18	44	0.69 (0.39–1.21)	0.20
Rec Trt	11	16	1.09 (0.52–2.30)	0.81	25	—	0.90 (0.29–2.78)	0.86

Median survival not calculable for missing values. OS, overall survival; HNCSS, head and neck cancer-specific survival; HPV, human papillomavirus; HR, hazard ratio; CI, confidence interval; Rec Trt, recommended treatment.